Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients

E-resources

Peer reviewed

Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients

Afanasiev, Vadim; Demeret, Sophie; Bolgert, Francis; Eymard, Bruno; Laforêt, Pascal; Benveniste, Olivier

Neuromuscular disorders : NMD, 03/2017, Volume: 27, Issue: 3

Journal Article

Highlights • In case of immunosuppressant-resistant myasthenia gravis, rituximab appears to be efficient in 50%. • The treatment with rituximab may be considered as an early 3rd line therapy in the management of severe myasthenia gravis. • Rituximab increases the risk of progressive multifocal leukoencephalopathy in patients with myasthenia gravis under chronic immunosuppressant therapy. • Rituximab seems to reduce the use of prednisone in case of resistant myasthenia gravis.

Keep searching

Author

Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.

Year	Impact factor		Edition		Category		Classification
Year	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Links to authors' personal bibliographies	Links to information on researchers in the SICRIS system

Source: Personal bibliographies and: SICRIS

Upload image

Shelf entry

Adding material to shelf was successful.

Adding material to shelf failed.

It was not necessary to add the material to the shelf.

Permalink

E-mail

Impact factor

Select the library membership card:

DRS, in which the journal is indexed

Citations

Theme